Invivyd stock (US46186M1080): Q1 2026 earnings report released
Published on 05/14/2026 at 11:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Invivyd (NASDAQ:IVVD), a commercial-stage biopharmaceutical company, published its first-quarter 2026 earnings report on May 14, 2026. The stock closed at $1.47 USD on Nasdaq, down 1.34% from the prior session, according to MarketBeat as of 05/14/2026. Extended trading saw it at $1.46, a further 0.68% drop. Investors await detailed financial metrics and updates on its infectious disease pipeline.
As of: 14.05.2026
By the editorial team – specialized in equity coverage.
At a glance
- Name: Invivyd, Inc.
- Sector/industry: Biopharmaceuticals
- Headquarters/country: United States
- Core markets: Infectious diseases, US
- Key revenue drivers: Antibody-based therapeutics
- Home exchange/listing venue: Nasdaq (IVVD)
- Trading currency: USD
Official source
For first-hand information on Invivyd, visit the company’s official website.
Go to the official websiteInvivyd: core business model
Invivyd develops and commercializes antibody-based solutions targeting infectious diseases, primarily in the United States. The company, listed on Nasdaq under ticker IVVD, emphasizes monoclonal antibodies for prevention and treatment of viral infections, according to its profile on MarketBeat as of 05/14/2026. This focus positions it in the growing biopharma segment addressing unmet needs in pandemics and seasonal illnesses.
Recent advancements include progress in the REVOLUTION program and a novel measles monoclonal antibody candidate VMS063, highlighted in company news. Invivyd's model relies on discovery, clinical development, and commercialization, with a commercial-stage pipeline that appeals to US investors tracking biotech innovations.
Main revenue and product drivers for Invivyd
Invivyd's revenue stems from its antibody portfolio, with emphasis on products for infectious diseases like COVID-19 variants and emerging viruses. Q1 2026 results, released today, are expected to detail sales performance amid market dynamics, per MarketBeat as of 05/14/2026. Key drivers include regulatory approvals and commercialization milestones that enhance US market penetration.
Pipeline candidates like VMS063 represent potential first-in-class therapies, supporting long-term revenue growth. For US investors, Invivyd's Nasdaq listing and focus on high-demand therapeutics provide exposure to biotech trends.
Industry trends and competitive position
The biopharma sector for infectious diseases sees rising demand due to evolving pathogens, with antibody therapies gaining traction post-COVID. Invivyd competes by advancing half-life extended monoclonals, differentiating through potency and breadth of coverage. Its US headquarters align with key regulatory and market opportunities.
Why Invivyd matters for US investors
Listed on Nasdaq, Invivyd offers US investors direct access to innovative antibody solutions amid ongoing infectious disease challenges. The company's pipeline addresses public health priorities, potentially benefiting from US funding and demand in healthcare.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Conclusion
Invivyd's Q1 2026 earnings release marks a key moment for monitoring its commercial progress and pipeline updates. With a recent stock dip to $1.47 on Nasdaq, the biopharma firm's focus on infectious disease antibodies remains central. US investors track such developments for insights into biotech resilience and growth potential.
Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
